"There is only one-criterion to be included among the Dividend Kings: a publicly-traded company must increase its total fiscal-year dividend-payout for a minimum of 50 consecutive years." - Dogs of...

AbbVie Inc. ABBV said Monday the U.S. Food and Drug Administration has granted breakthrough therapy designation, or BTD, to its epocritamab treatment for relapsed or refractory (R/R) follicular lym...

Even in today's overvalued market, Warren Buffett-style "wonderful companies at fair prices" are plentiful. That includes dividend aristocrats, the world's most dependable sources of steadily growi...

As the global economic landscape evolves, identifying burgeoning companies with potential to scale into trillion-dollar entities is a pursuit that captivates investors worldwide. In the realm of ph...

AbbVie is a Dividend King with a bright future. Eli Lilly's dividend is just icing on the cake, with the company's growth prospects taking center stage.

AbbVie has many drugs in its portfolio that can generate more than $1 billion each in annual revenue. The company generates strong free cash flow to support its dividend as well as growth opportuni...

Investors with an interest in Large Cap Pharmaceuticals stocks have likely encountered both AbbVie (ABBV) and Eli Lilly (LLY). But which of these two stocks offers value investors a better bang for...

Despite his reputation as a growth investor, Peter Lynch offers valuable insights into dividend stocks, too. These insights are often overlooked by many of us due to his success with high-growth st...

While it's always important to consider passive-income providers, they often lack an underlying growth impetus, which subsequently makes the concept of high-yield dividend growth stocks so compelli...

While getting to retirement age can be a blessing and a curse, the reality of counting on the U.S.

Before extolling the benefits of high-yield blue-chip stocks, it's important to acknowledge the reality that many investors are feeling. Long-term stock investors have had to muddle through challen...

There are many ways to make money on Wall Street. One of the best proven strategies is buying and holding dividend stocks for long-term wealth creation.

AbbVie looks like a bargain that has stronger growth on the way. Axsome Therapeutics is in the early innings of what could be an exciting growth story.

"Dividend Aristocrats in the S&P 500 Index… have raised their annual payouts every year for at least 25 consecutive years. "-- Kiplinger.com/Investing. 66 Aristocrats, screened as of November 6, 20...

With much of the U.S. stock market in a correction there are plenty of attractive stocks to consider. This is especially true in income investing.